NO179789C - Arylacetamider - Google Patents

Arylacetamider

Info

Publication number
NO179789C
NO179789C NO931681A NO931681A NO179789C NO 179789 C NO179789 C NO 179789C NO 931681 A NO931681 A NO 931681A NO 931681 A NO931681 A NO 931681A NO 179789 C NO179789 C NO 179789C
Authority
NO
Norway
Prior art keywords
arylacetamide
arylacetamides
bind
novel
formula
Prior art date
Application number
NO931681A
Other languages
English (en)
Norwegian (no)
Other versions
NO931681L (no
NO931681D0 (no
NO179789B (no
Inventor
Rudolf Gottschlich
Karl-August Ackermann
Helmut Prucher
Christoph Seyfried
Hartmut Greiner
Gerd Bartoszyk
Frank Mauler
Manfred Stohrer
Andrew Barber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO931681D0 publication Critical patent/NO931681D0/no
Publication of NO931681L publication Critical patent/NO931681L/no
Publication of NO179789B publication Critical patent/NO179789B/no
Publication of NO179789C publication Critical patent/NO179789C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • C07D311/84Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
NO931681A 1992-05-09 1993-05-07 Arylacetamider NO179789C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4215213A DE4215213A1 (de) 1992-05-09 1992-05-09 Arylacetamide

Publications (4)

Publication Number Publication Date
NO931681D0 NO931681D0 (no) 1993-05-07
NO931681L NO931681L (no) 1993-11-10
NO179789B NO179789B (no) 1996-09-09
NO179789C true NO179789C (no) 1996-12-18

Family

ID=6458428

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931681A NO179789C (no) 1992-05-09 1993-05-07 Arylacetamider

Country Status (22)

Country Link
US (1) US5532266A (xx)
EP (1) EP0569802B1 (xx)
JP (1) JP3210771B2 (xx)
KR (1) KR100241637B1 (xx)
CN (1) CN1041087C (xx)
AT (1) ATE168368T1 (xx)
AU (1) AU662051B2 (xx)
BR (1) BR1100581A (xx)
CA (1) CA2095797C (xx)
CZ (1) CZ289961B6 (xx)
DE (2) DE4215213A1 (xx)
DK (1) DK0569802T3 (xx)
ES (1) ES2121030T3 (xx)
HK (1) HK1011990A1 (xx)
HU (1) HU214578B (xx)
NO (1) NO179789C (xx)
PL (1) PL173779B1 (xx)
RU (1) RU2125041C1 (xx)
SK (1) SK282646B6 (xx)
TW (1) TW372961B (xx)
UA (1) UA32543C2 (xx)
ZA (1) ZA933222B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137571A (en) * 1990-06-05 1992-08-11 Rohm And Haas Company Method for improving thickeners for aqueous systems
DE4407047A1 (de) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
WO1996006078A1 (en) * 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU3172397A (en) * 1996-06-05 1998-01-05 Novartis Ag Anti-neurodegeneratively effective xanthene derivatives
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2007207867B2 (en) * 2001-04-05 2009-09-24 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of bladder diseases
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
KR101108014B1 (ko) 2002-05-17 2012-01-25 티오가 파마슈티칼스, 인코포레이티드 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US6852713B2 (en) * 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
AU2004288641B2 (en) * 2003-10-30 2010-08-12 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
US7288543B2 (en) * 2004-03-12 2007-10-30 Eli Lilly And Company Opioid receptor antagonists
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
JP5776554B2 (ja) * 2009-11-18 2015-09-09 日本ゼオン株式会社 フルオレン化合物、当該フルオレン化合物を含有する合成ポリマーの安定化剤、及び当該フルオレン化合物を含有する組成物
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
CA3034211A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
CA3047325A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) * 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) * 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
GB8601796D0 (en) * 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
EP0330467A1 (en) * 1988-02-23 1989-08-30 Glaxo Group Limited Heterocyclic compounds
DE3935371A1 (de) * 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3916663A1 (de) * 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO1991008206A1 (en) * 1989-11-24 1991-06-13 Dr. Lo. Zambeletti S.P.A. N-acyl-substituted azacyclic compounds, processes for their preparation, and their use as pharmaceuticals
GB8926560D0 (en) * 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals

Also Published As

Publication number Publication date
DE59308763D1 (de) 1998-08-20
CZ289961B6 (cs) 2002-05-15
CN1041087C (zh) 1998-12-09
HU9301325D0 (en) 1993-09-28
NO931681L (no) 1993-11-10
RU2125041C1 (ru) 1999-01-20
ATE168368T1 (de) 1998-08-15
HU214578B (hu) 1998-04-28
TW372961B (en) 1999-11-01
JP3210771B2 (ja) 2001-09-17
HK1011990A1 (en) 1999-07-23
NO931681D0 (no) 1993-05-07
US5532266A (en) 1996-07-02
NO179789B (no) 1996-09-09
SK282646B6 (sk) 2002-10-08
DK0569802T3 (da) 1999-04-19
EP0569802B1 (de) 1998-07-15
BR1100581A (pt) 2000-08-01
AU3834193A (en) 1993-11-11
KR930023340A (ko) 1993-12-18
SK46893A3 (en) 1994-04-06
CA2095797C (en) 2007-09-18
CZ82393A3 (en) 1994-02-16
CA2095797A1 (en) 1993-11-10
AU662051B2 (en) 1995-08-17
UA32543C2 (uk) 2001-02-15
KR100241637B1 (ko) 2000-03-02
PL173779B1 (pl) 1998-04-30
EP0569802A1 (de) 1993-11-18
CN1079219A (zh) 1993-12-08
ZA933222B (en) 1993-12-08
PL298845A1 (en) 1994-01-10
DE4215213A1 (de) 1993-11-11
HUT70172A (en) 1995-09-28
ES2121030T3 (es) 1998-11-16
JPH0649022A (ja) 1994-02-22

Similar Documents

Publication Publication Date Title
ATE168368T1 (de) Arylacetamide
RU93004806A (ru) Арилацетамиды, способ их получения и применения, фармацевтическая композиция
DE69320294T2 (de) Härtbare carbamat-funktionelle Polymerzusammensetzung
FR2705842B3 (fr) Ensemble d'entraînement pour électromobile.
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
FI943569A (fi) Hyviä liukenemisominaisuuksia omaavia farmaseuttisia koostumuksia
ATE199560T1 (de) Festphasensynthese von oligoribonucleotiden
FI930051A0 (fi) 4,13-dioxabicyklo(8.2.1)tridecenonderivat sam foerfarande och mellanprodukt foer deras framstaellning
NO954799D0 (no) Blandinger for å modifisere ballistiske egenskaper
IT1267377B1 (it) Composizione erbicida con ridotta fitotossicita'
IS1605B (is) Botnv”rpuutbunathur
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
FR2679213B3 (fr) Poulie d'enroulement pour chaines.
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
ITRM920498A1 (it) Composizione per l'ignifugazione delle materie polimere.
ZA937179B (en) Tetrahydorindazolone pharmaceutical compositions
IT1265313B1 (it) Sulfonilammino tiofeni ad attivita' antiinfiammatoria, analgesica ed antipiretica
ITRM930635A0 (it) Composizione per biscotti aventi proprieta' antiacide.
IT1261660B (it) Composti dotati di caratteristiche fotocromatiche in presenza di ossigeno e metodi per la loro preparazione
FI930513A0 (fi) Uppbaerning och koerning i alla riktningar av en fjaederfaeuppsamlingsmaskins samlarhuvud och en foerlyttningstransportoers aenda medan den egentliga maskinenheten haolls pao sin plats
LV5828B4 (lv) Modificets pseudomonas eksotoksins PE 40
AU8377691A (en) Use of N-(1-hexahydroazepinylalkyl)acetamides for the treatment of cholinergic transmission disorders
ES1018650Y (es) "mampara plegable"
ITMI932506A0 (it) Procedimento per ottenere articoli per saggi immunologici a migliorate proprieta'

Legal Events

Date Code Title Description
MK1K Patent expired